poisar

Stocks · News reference

Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

Benzinga Newsdesk

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $104.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PTCT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Emma Newbery

    Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge

    The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.

    NVDAPCVXGMABPTCTTSM
  3. SEC EDGAR

    8-K filing — PTC THERAPEUTICS, INC. (PTCT)

    Filed: 2026-09-21 AccNo: 0001070081-26-000023 Size: 190 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    PTCT